Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of SGLT2i in noHCM With HFpEF
NCT06401343Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), sponsored by National Center for Cardiovascular Disease. Started Aug 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06401343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401343.